首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1532555

注射细胞毒性药物市场 - 按药物类别（抗代谢物、长春花生物碱、紫杉烷类、蒽环类、铂化合物、烷化剂）、按应用（肿瘤、类风湿关节炎）、按配销通路- 预测（2024 - 2032）

Injectable Cytotoxic Drugs Market - By Drug Class (Antimetabolites, Vinca Alkaloids, Taxanes, Anthracyclines, Platinum Compounds, Alkylating Agents), By Application (Oncology, Rheumatoid Arthritis), By Distribution Channel - Forecast (2024 - 2032)

出版日期: 2024年05月23日 | 出版商:

Global Market Insights Inc. | 英文 119 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在药物配方进步和肿瘤药物开发成长的推动下，2024年至2032年全球注射细胞毒性药物市场复合年增长率将达到5.8%。药物配方的创新，例如即用型注射剂和改进的输送系统，提高了治疗效率和患者的依从性。此外，新的肿瘤药物的持续开发扩大了可用疗法的范围，为各种癌症提供了更有针对性和更有效的治疗选择。这些进步透过满足不断变化的临床需求和增加患者获得先进治疗的机会来改善治疗结果并刺激市场成长。

例如，2023 年 6 月，美国 FDA 批准了 Amneal Pharmaceuticals 的 PEMRYDI RTU，这是一种即用型肿瘤注射。它适用于转移性非鳞状非小细胞肺癌的初始治疗，与派姆单抗和铂类化疗一起用于无特定基因组突变的患者。这项批准凸显了注射细胞毒性药物的持续创新，特别是对于复杂的癌症治疗。它强调了对个人化医疗和联合疗法的日益关注，这可能会推动对先进注射细胞毒性药物的需求增加，并有助于市场成长和多元化。

注射细胞毒性药物产业根据类别、应用、配销通路和地区进行分类。

由于长春花生物碱在治疗白血病和淋巴瘤等多种癌症方面的功效已被证实，因此到 2032 年，长春花生物碱领域将出现显着的改善。这些药物，如长春新碱和长春花碱，透过破坏癌细胞分裂发挥作用，这使得它们在化疗方案中至关重要。它们有据可查的成功和在肿瘤学领域的持续使用有助于其占据市场主导地位。新配方和联合疗法的持续开发进一步支持了长春花生物碱领域的成长和突出。

由于这种慢性发炎性疾病的高盛行率以及细胞毒性药物在治疗严重病例方面的有效性，类风湿性关节炎细分市场将在 2024 年至 2032 年间出现显着的激增。注射细胞毒性药物，例如甲氨蝶呤，对于减少发炎和减缓疾病进展至关重要，可以显着缓解患者的症状。人们对治疗方案的认识不断提高，以及这些疗法在类风湿性关节炎治疗中的采用率不断提高，推动了该细分市场的突出地位，从而奠定了其领先的市场地位。

由于医疗基础设施的快速发展和癌症发生率的上升，亚太地区注射细胞毒性药物市场将在 2024 年至 2032 年间获得相当大的份额。该地区不断增长的人口、癌症治疗意识的提高以及对医疗保健技术的大量投资推动了对先进注射细胞毒性药物的需求。此外，主要製药公司的存在和强劲的研发活动进一步支持了市场成长。亚太地区充满活力的医疗保健格局和对改善癌症护理的关注使其成为全球注射细胞毒性药物行业的关键贡献者。

产业生态系统分析
产业影响力
- 成长动力
  - 癌症和类风湿性关节炎的发生率增加
  - 越来越多的监管机构批准注射细胞毒性药物
  - 增加对精准肿瘤疗法开发的投资
  - 癌症护理设施迅速增加
- 产业陷阱与挑战
  - 药物研发成本高
  - 强有力的替代疗法的存在
成长潜力分析
未来市场趋势
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

主要趋势
抗代谢药
长春花生物碱
紫杉烷类
蒽环类药物
铂化合物
烷基化剂
其他药物类别

第 6 章：市场估计与预测：按配销通路划分，2021 - 2032 年

主要趋势
医院药房
零售药局
网路药局

第 7 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
肿瘤学
类风湿关节炎
多发性硬化症
其他应用

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Abbvie Inc
Accord Healthcare, Inc.
Amgen, Inc.
Baxter International Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Fresenius Kabi AG
Johnson and Johnson Services Inc.
Merck & Co. Inc.
Novartis AG
Pfizer, Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

简介目录

Product Code: 9610

Global Injectable Cytotoxic Drugs Market will garner a 5.8% CAGR from 2024 to 2032, fueled by advancements in drug formulations and growth in oncology drug development. Innovations in drug formulations, such as ready-to-use injectables and improved delivery systems, enhance treatment efficiency and patient compliance. Furthermore, the continuous development of new oncology drugs expands the range of available therapies, offering more targeted and effective treatment options for various cancers. These advancements improve therapeutic outcomes and stimulate market growth by addressing evolving clinical needs and increasing patient access to advanced treatments.

For instance, in June 2023, the US FDA approved Amneal Pharmaceuticals' PEMRYDI RTU, a ready-to-use oncology injectable. It is indicated for initial treatment of metastatic non-squamous non-small cell lung cancer, used with pembrolizumab and platinum chemotherapy in patients without specific genomic mutations. The approval highlights the ongoing innovation in injectable cytotoxic drugs, particularly for complex cancer treatments. It underscores a growing focus on personalized medicine and combination therapies, which could drive increased demand for advanced injectable cytotoxic drugs and contribute to market growth and diversification.

The injectable cytotoxic drugs industry is classified based on class, application, distribution channel, and region.

The vinca alkaloids segment will encounter a marked upturn through 2032 due to their established efficacy in treating various cancers, including leukemia and lymphoma. These drugs, such as vincristine and vinblastine, work by disrupting cancer cell division, making them essential in chemotherapy regimens. Their well-documented success and continued use in oncology contribute to their dominant market position. The ongoing development of new formulations and combination therapies further supports the growth and prominence of the vinca alkaloids segment.

The rheumatoid arthritis segment will observe a noteworthy surge between 2024 and 2032, driven by the high prevalence of this chronic inflammatory condition and the effectiveness of cytotoxic drugs in managing severe cases. Injectable cytotoxic drugs, such as methotrexate, are crucial in reducing inflammation and slowing disease progression, providing significant relief for patients. The growing awareness of treatment options and increasing adoption of these therapies in rheumatoid arthritis management drive the segment's prominence, contributing to its leading market position.

Asia Pacific injectable cytotoxic drugs market will achieve a decent share from 2024 to 2032, attributed to rapidly growing healthcare infrastructure and increasing incidence of cancer. The region's expanding population, rising awareness of cancer treatments, and substantial investments in healthcare technology drive demand for advanced injectable cytotoxic drugs. Additionally, the presence of major pharmaceutical companies and robust R&D activities further support market growth. Asia Pacific's dynamic healthcare landscape and focus on improving cancer care position it as a pivotal contributor to the global injectable cytotoxic drugs industry.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of cancer and rheumatoid arthritis
  - 3.2.1.2 Growing regulatory approvals for injectable cytotoxic drugs
  - 3.2.1.3 Increasing investments for the development of precision oncology therapies
  - 3.2.1.4 Rapid increase in cancer care facilities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High drug development cost
  - 3.2.2.2 Presence of strong alternative therapies
3.3 Growth potential analysis
3.4 Future market trends
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Antimetabolites
5.3 Vinca alkaloids
5.4 Taxanes
5.5 Anthracyclines
5.6 Platinum compounds
5.7 Alkylating agents
5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Hospital pharmacies
6.3 Retail pharmacies
6.4 Online pharmacies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oncology
7.3 Rheumatoid arthritis
7.4 Multiple sclerosis
7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa